TITLE

Crizotinib Capsules (Xalkori)

AUTHOR(S)
Elliott, William T.; James Chan
PUB. DATE
September 2011
SOURCE
Internal Medicine Alert;9/29/2011, Vol. 33 Issue 18, p142
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on crizotinib, marketed as Xalkori®, a new drug approved by the Food and Drug Administration (FDA) as an effective oral treatment for non-small cell lung cancer (NSCLC). It mentions that NSCLC patients can take 250 mg of crizotinib twice daily with or without food intake. It states that crizotinib has several common adverse events such as vision disorders, gastrointestinal-related events, and edema and severe adverse events such as fatal pneumonitis.
ACCESSION #
66387043

 

Related Articles

  • Celgene receives FDA fast track designation for lung cancer drug.  // PharmaWatch: Cancer;Oct2008, Vol. 7 Issue 10, p17 

    The article reports on the fast track designation received by Amrubicin from the U.S. Food and Drug Administration for the treatment of small cell lung cancer after first-line chemotherapy. Amrubicin is a third-generation, synthetic anthracycline analogue developed by Celgene Corp. It has...

  • Proellex put on clinical hold.  // Reactions Weekly;8/15/2009, Issue 1265, p2 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to put a clinical hold on Repros Therapeutics' investigational New Drug Applications (IND) for Proellex due to safety concerns. The company earlier decided to suspend dosing of the progesterone receptor...

  • Three new FDA approvals for HIV. Highleyman, Liz // Bay Area Reporter;8/5/2004, Vol. 34 Issue 32, p16 

    Reports on the approval of several new products for people with HIV by the Food and Drug Administration in the U.S. Consent given to the new fixed-dose combination pills Truvada and Epzicom; Adverse effect of Abacavir; Content of Truvada from Gilead Sciences.

  • A 4-Drug Combination (Viekira Pak) for Hepatitis C.  // JAMA: Journal of the American Medical Association;5/12/2015, Vol. 313 Issue 18, p1857 

    The article discusses Viekira Pak, a four-drug combination approved by the U.S. Food and Drug Administration (FDA) for the oral treatment of chronic hepatitis C virus (HCV) genotype one infection. Details are provided on the inclusion of drugs such as ombitasvir, paritaprevir, and dasabuvir in...

  • Pharmacyclics files cancer drug over protest.  // PharmaWatch: Cancer;May2007, Vol. 6 Issue 5, p16 

    The article reports that Pharmacyclics Inc. has filed a drug application called "over protest" for its cancer drug Xcytrin as a way of getting a drug reviewed when there is a disagreement with regulators over the acceptability of a submission. The application seeks approval to market the drug...

  • Gefitinib approved for lung cancer.  // WHO Drug Information;2003, Vol. 17 Issue 2, p102 

    Reports that the U.S. Food and Drug Administration (FDA) has announced the approval of gefitinib tablets as a single agent treatment for patients with advanced non small-cell lung cancer. Approval of gefitinib as a treatment for patients whose cancer has continued to progress despite treatment...

  • FDA APPROVES MILNACIPRAN HCI FOR THE MANAGEMENT OF FIBROMYALGIA. Stoltzfoos, Lonnie // Primary Psychiatry;Feb2009, Vol. 16 Issue 2, p17 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve milnacipran HCI for the treatment of fibromyalgia. It cites that milnacipran HCI is a selective serotonin and norepinephrine dual reuptake inhibitor that will be available in 12.5-milligrams (mg),...

  • Trospium Chloride (Sanctura®) - New to the U.S. for Overactive Bladder. Gaines, Kaye K. // Urologic Nursing;Feb2005, Vol. 25 Issue 1, p64 

    Focuses on the approval given to the trospium chloride, an anticholinergic agent, from Indevus Pharmaceuticals by the U.S. Food and Drug Administration for the treatment of overactive bladder and its associated symptoms of urinary urgency, frequency, and incontinence. Estimation of the...

  • FDA OKs New Drug For Schizophrenia.  // RN;Feb2007, Vol. 70 Issue 2, p57 

    The reports on the approval of the extended-release drug paliperidone (Invega) as treatment for schizophrenia by the U.S. Food and Drugs Administration (FDA). Paliperidone is an atypical antipsychotic drug which should be taken orally in doses ranging from 3-15 milligram a day. It has been...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics